Abstract
Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Cancer Vaccines / adverse effects
-
Cancer Vaccines / immunology*
-
Cell Division
-
DNA, Viral / analysis
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Glutathione Transferase / immunology
-
Humans
-
Immunity, Cellular / physiology
-
Immunization Schedule
-
Immunization, Secondary*
-
Immunoglobulin G / analysis
-
Immunoglobulin G / biosynthesis
-
Interferon-gamma / metabolism
-
Papillomaviridae / immunology*
-
Phytohemagglutinins / immunology
-
T-Lymphocytes / immunology
-
T-Lymphocytes / metabolism
-
Uterine Cervical Dysplasia / immunology*
-
Uterine Cervical Dysplasia / pathology
-
Vaccinia virus / immunology*
-
Vulva / pathology
Substances
-
Cancer Vaccines
-
DNA, Viral
-
Immunoglobulin G
-
Phytohemagglutinins
-
Interferon-gamma
-
Glutathione Transferase